SCHEMBL4243085

SCHEMBL4243085

CC(C)(C)OC(=O)N1CC2CCC1(CO)CC2

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.40
CHRM2 P08172 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
KMT2A Q03164 1/20 0.34
HSD11B1 P28845 2/20 0.33
HPGD P15428 1/20 0.33
ABCB1 P08183 1/20 0.33
EPHX2 P34913 1/20 0.33
DDB1 Q16531 2/20 0.32
CRBN Q96SW2 2/20 0.32
KDM4E B2RXH2 1/20 0.32
PKM P14618 1/20 0.32
NAMPT P43490 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30646636 0.91 NR1H2 (0.38) NR1H2CHRM2CHRM1CHRM3MEN1
SCHEMBL8386681 0.91 NR1H2 (0.38) NR1H2CHRM2CHRM1CHRM3MEN1
SCHEMBL22203885 0.91 NR1H2 (0.38) NR1H2CHRM2CHRM1CHRM3MEN1
SCHEMBL16391862 0.84 NR1H2 (0.42) NR1H2CHRM2CHRM1CHRM3MEN1
SCHEMBL20990299 0.84 NR1H2 (0.42) NR1H2CHRM2CHRM1CHRM3MEN1
SCHEMBL16391793 0.81 NR1H2 (0.35) NR1H2CHRM2CHRM1CHRM3MEN1
SCHEMBL16392154 0.81 NR1H2 (0.35) NR1H2CHRM2CHRM1CHRM3MEN1
SCHEMBL30646546 0.77 HSD11B1 (0.33) NR1H2CHRM2CHRM1CHRM3HSD11B1
SCHEMBL16034147 0.77 CHRM2 (0.37) NR1H2CHRM2CHRM1CHRM3MEN1
SCHEMBL22338021 0.76 CHRM2 (0.39) NR1H2CHRM2CHRM1CHRM3HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030033-A1 Novel Compounds 894 ASTRAZENECA AB (SE) 2009-01-29 US disclosed
US-20090030033-A1 Novel Compounds 894 ASTRAZENECA AB (SE) 2009-01-29 US disclosed
US-20090030033-A1 Novel Compounds 894 ASTRAZENECA AB (SE) 2009-01-29 US disclosed
WO-2009013535-A1 2-AZABICYCLO(2.2.2)OCTANE DERIVATIVES AS MODULATORS OF THE GLYCINE TRANSPORTER I RECEPTOR ASTRAZENECA AB (SE) 2009-01-29 WO disclosed
WO-2009013535-A1 2-AZABICYCLO(2.2.2)OCTANE DERIVATIVES AS MODULATORS OF THE GLYCINE TRANSPORTER I RECEPTOR ASTRAZENECA AB (SE) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030033-A1 Novel Compounds 894 AZI2, TPMT, AMPD2 NR1H2 2930/4885CHRM2 2365/4885CHRM1 2697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.